Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133761 | 0.90 | CTNNB1 (0.43) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL17030555 | 0.90 | CTNNB1 (0.40) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL3642604 | 0.86 | CHRM2 (0.47) | KCNH2 | |
| SCHEMBL9382838 | 0.83 | MEN1 (0.46) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL28880617 | 0.83 | RAB9A (0.47) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL1464785 | 0.80 | CD274 (0.50) | RAB9A | |
| SCHEMBL1346477 | 0.78 | MAOB (0.47) | RAB9AMAOAMAOBNPC1 | |
| SCHEMBL11297162 | 0.77 | ACACB (0.45) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL1721517 | 0.77 | SLC5A2 (0.38) | KCNH2 | |
| SCHEMBL4133763 | 0.77 | KCNH2 (0.46) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0794183-B1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 2000-06-14 | — | — | EP | claimed |
| US-5693831-A | (2,3-dihydro-5-benzofuranyl)-acetonitrile | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | claimed |
| EP-0794183-A1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 1997-09-10 | — | — | EP | claimed |
| JP-9241250-A | — | — | None | — | — | JP | disclosed |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | ABBVIE S.Á.R.L. (LU) | 2018-11-06 | — | — | US | disclosed |
| WO-2017187321-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | AbbVie S.à.r.l. (LU) | 2017-11-02 | — | — | WO | disclosed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | disclosed |
| EP-0794183-B1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 2000-06-14 | — | — | EP | disclosed |
| EP-0794183-B1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 2000-06-14 | — | — | EP | disclosed |
| US-5693831-A | (2,3-dihydro-5-benzofuranyl)-acetonitrile | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5693831-A | (2,3-dihydro-5-benzofuranyl)-acetonitrile | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5693831-A | (2,3-dihydro-5-benzofuranyl)-acetonitrile | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| JP-H09241250-A | (2,3-DIHYDRO-5-BENZOFURANYL)ACETONITRILE | BAYER AG | 1997-09-16 | — | — | JP | disclosed |
| EP-0794183-A1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 1997-09-10 | — | — | EP | disclosed |
| EP-0794183-A1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 1997-09-10 | — | — | EP | disclosed |
| EP-0794183-A1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 1997-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | CFTR, CHRM2, CHRM1 | RAB9A 877/4885KDM1A 4740/4885MAOA 4744/4885 |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | CFTR, CHRM2, CHRM1 | RAB9A 877/4885KDM1A 4740/4885MAOA 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.